--- title: "bioAffinity Tech | 10-Q: FY2026 Q1 Revenue: USD 1.352 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286031553.md" datetime: "2026-05-12T03:57:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286031553.md) - [en](https://longbridge.com/en/news/286031553.md) - [zh-HK](https://longbridge.com/zh-HK/news/286031553.md) --- # bioAffinity Tech | 10-Q: FY2026 Q1 Revenue: USD 1.352 M Revenue: As of FY2026 Q1, the actual value is USD 1.352 M. EPS: As of FY2026 Q1, the actual value is USD -0.81. EBIT: As of FY2026 Q1, the actual value is USD -3.612 M. #### Segment Revenue - **Diagnostic Research & Development (R&D)**: Net revenues were $1,131 for the three months ended March 31, 2026, compared to $0 for the same period in 2025. - **Laboratory Services**: Net revenues were $1,350,396 for the three months ended March 31, 2026, compared to $1,853,597 for the same period in 2025. - **Total Net Revenue**: Total net revenue was $1,351,527 for the three months ended March 31, 2026, a decrease of approximately 36% from $1,853,597 for the three months ended March 31, 2025. This decrease was primarily due to discontinuing certain unprofitable pathology services in March 2025 to focus on high-margin services, partially offset by increased revenue from bioAffinity Technologies, Inc.’s CyPath® Lung diagnostic test. #### Operating Expenses by Segment - **Diagnostic R&D**: Operating expenses were - $683,747 for the three months ended March 31, 2026, compared to - $505,739 for the same period in 2025. - **Laboratory Services**: Operating expenses were - $1,832,592 for the three months ended March 31, 2026, compared to - $2,267,656 for the same period in 2025. - **General Corporate Activities**: Operating expenses were - $2,452,164 for the three months ended March 31, 2026, compared to - $1,707,341 for the same period in 2025. - **Total Operating Loss**: Total operating loss was - $3,616,976 for the three months ended March 31, 2026, compared to - $2,627,139 for the same period in 2025. #### Overall Operational Metrics - **Net Loss**: Net loss for the three months ended March 31, 2026, was - $3,630,610, compared to - $2,660,417 for the three months ended March 31, 2025. - **Direct Costs and Expenses**: Decreased by - $439,224, or -32%, to $928,636 for the three months ended March 31, 2026, from $1,367,860 in 2025, primarily due to strategic actions in March 2025 to streamline operations and reduce lab costs. - **Research and Development**: Decreased by - $17,679, or -5%, to $349,707 for the three months ended March 31, 2026, from $367,386 in 2025, mainly due to lower compensation costs, benefits, and lab supplies. - **Clinical Development**: Increased by $195,687, or 141%, to $334,040 for the three months ended March 31, 2026, from $138,353 in 2025, primarily due to the commencement of a pivotal clinical trial. - **Selling, General and Administrative**: Increased by $789,053, or 32%, to $3,241,602 for the three months ended March 31, 2026, from $2,452,549 in 2025, mainly due to increased employee compensation for administrative and sales personnel to support CyPath® Lung sales growth. - **Depreciation and Amortization**: Decreased by - $40,070, or -26%, to $114,518 for the three months ended March 31, 2026, from $154,588 in 2025, primarily due to the termination of a financing lease in April 2025. - **Total Operating Expenses**: Increased by $487,767, or 11%, to $4,968,503 for the three months ended March 31, 2026, from $4,480,736 in 2025. - **Total Other (Expense) Income**: - $13,634 for the three months ended March 31, 2026, compared to - $24,583 for the same period in 2025, a decrease of -45%. #### Cash Flow - **Net Cash Used in Operating Activities**: - $3,227,240 for the three months ended March 31, 2026, compared to - $1,641,775 for the same period in 2025. - **Net Cash Used in Investing Activities**: - $5,663 for the three months ended March 31, 2026, compared to - $50,786 for the same period in 2025. - **Net Cash Used in Financing Activities**: - $118,513 for the three months ended March 31, 2026, compared to $1,031,976 for the same period in 2025. - **Cash and Cash Equivalents at End of Period**: $3,098,366 as of March 31, 2026, compared to $444,706 as of March 31, 2025. #### Unique Metrics - **CyPath® Lung Unit Sales Growth**: Achieved 146% growth in the first quarter of 2026 compared to the first quarter of 2025. - **CyPath® Lung Testing Revenue**: Increased approximately 114% to $361,000 for the three months ended March 31, 2026, compared to $169,000 for the same period in 2025. - **Accumulated Deficit**: - $72.2 million as of March 31, 2026. - **Working Capital**: Approximately $1.2 million as of March 31, 2026. #### Future Outlook and Strategy bioAffinity Technologies, Inc. expects its current cash and anticipated revenue to support operations through June 2026 and indicates substantial doubt about its ability to continue as a going concern for the next twelve months without additional capital. The company plans to raise further capital through equity or debt, strategic partnerships, or grants to fund future operations and expand commercialization efforts. Strategic initiatives include advancing therapeutic discoveries for cancer treatments, seeking FDA de novo classification for CyPath® Lung, and commercializing CyPath® Lung as a CE-marked test in the European Union with partners. ### Related Stocks - [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md) ## Related News & Research - [Adval Tech holds annual shareholder meeting, approves all proposals](https://longbridge.com/en/news/287248506.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md) - [Ravelin Properties REIT Reports First Quarter 2026 Results | SLTTF Stock News](https://longbridge.com/en/news/286625033.md) - [Tech platform Treasure Global posts $1 mln gain from subsidiary disposal in Q3](https://longbridge.com/en/news/287218926.md) - [Alldigi Tech Publishes Notice on Special Demat Window for Physical Shares](https://longbridge.com/en/news/287217437.md)